Nvidia Corporation and Eli Lilly and Company have announced the creation of a first-of-its-kind AI co-innovation lab aimed at transforming drug discovery through artificial intelligence. The two companies will jointly invest up to $1 billion over five years in infrastructure, talent, and research.

The lab, based in the San Francisco Bay Area, will leverage NVIDIA’s BioNeMo platform and Vera Rubin architecture, combining Lilly’s expertise in medicine with Nvidia’s strengths in AI and accelerated computing. The collaboration will focus on developing advanced AI models and robotics to accelerate and scale the discovery and production of new medicines.